{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:27Z","timestamp":1791327327951,"version":"4.3.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hematologic malignancies in older people are unlikely to be cured with chemotherapy alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially nonmyeloablative (NMA) conditioning and the use of haploidentical donors, now make this therapy available to older people; however, long-term outcomes and predictors of success are unclear. We reviewed the outcomes of 93 consecutive patients aged 70 and older (median, 72; range, 70-78), who underwent haploidentical BMT at Johns Hopkins Hospital between 1 September 2009 and 1 April 2018. All patients received NMA conditioning and posttransplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis. The 2-year overall survival was 53%, and 2-year event-free survival was 43%. The 180-day cumulative incidence (CuI) of nonrelapse mortality (NRM) was 14%, and the 2-year CuI was 27%. The 2-year CuI of relapse was 30%. Of 78 patients who were alive and had their weight recorded on day 180, weight loss predicted subsequent NRM (subdistribution hazard ratio, 1.0; 95% CI, 1-1.13; P = .048). In conclusion, haploidentical BMT with PTCy is feasible and relatively safe in septuagenarians. Although early, 6-month NRM was relatively low at 14%, but overall NRM continued to climb to 27% at 2 years, at least in part because of late deaths that appeared to be somewhat age related. Further studies to elucidate predictors of NRM are warranted.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000155","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T20:45:20Z","timestamp":1567802720000},"page":"2608-2616","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70"],"prefix":"10.1182","volume":"3","author":[{"given":"Philip H.","family":"Imus","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"first","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Johns Hopkins\/Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2909-4170","authenticated-orcid":false,"given":"Patrick","family":"Lowery","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-8862","authenticated-orcid":false,"given":"Ivan M.","family":"Borrello","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode J.","family":"Swinnen","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8013-9886","authenticated-orcid":false,"given":"Christian B.","family":"Gocke","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abbas","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"Bola\u00f1os-Meade","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Varadhan","sequence":"first","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Johns Hopkins\/Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Hematologic Malignancy and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"issue":"19","key":"2020021316130956600_B1","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020021316130956600_B2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2020021316130956600_B3","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","author":"Vasu","year":"2018","journal-title":"Blood Adv"},{"issue":"1 suppl","key":"2020021316130956600_B4","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.bbmt.2011.11.003","article-title":"From biology to clinical practice: aging and hematopoietic cell transplantation","volume":"18","author":"Artz","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020021316130956600_B5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","article-title":"Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age","volume":"105","author":"Alyea","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2020021316130956600_B6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2020021316130956600_B7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jgo.2014.04.003","article-title":"Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients","volume":"5","author":"Keller","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"2020021316130956600_B8","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2020021316130956600_B9","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2020021316130956600_B10","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"issue":"28","key":"2020021316130956600_B11","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020021316130956600_B12","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021316130956600_B13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020021316130956600_B14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020021316130956600_B15","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bbmt.2017.06.019","article-title":"Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome","volume":"23","author":"Slade","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021316130956600_B16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020021316130956600_B17","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"23","key":"2020021316130956600_B18","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2020021316130956600_B19","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2018.01.011","article-title":"Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation","volume":"24","author":"Kasamon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021316130956600_B20","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020021316130956600_B21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"282","key":"2020021316130956600_B22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"P. Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2020021316130956600_B23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression Models and Life-Tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc [Ser A]"},{"issue":"446","key":"2020021316130956600_B24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"27","key":"2020021316130956600_B25","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"4","key":"2020021316130956600_B26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1532-5415.1995.tb05803.x","article-title":"Involuntary weight loss in older outpatients: incidence and clinical significance","volume":"43","author":"Wallace","year":"1995","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"2020021316130956600_B27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/oxfordjournals.aje.a009844","article-title":"Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women\u2019s Health Study","volume":"149","author":"French","year":"1999","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2020021316130956600_B28","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/archinte.165.9.1035","article-title":"Reasons for intentional weight loss, unintentional weight loss, and mortality in older men","volume":"165","author":"Wannamethee","year":"2005","journal-title":"Arch Intern Med"},{"issue":"17","key":"2020021316130956600_B29","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2010.1568","article-title":"Change in disability after hospitalization or restricted activity in older persons","volume":"304","author":"Gill","year":"2010","journal-title":"JAMA"},{"issue":"17","key":"2020021316130956600_B30","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.292.17.2115","article-title":"Hospitalization, restricted activity, and the development of disability among older persons","volume":"292","author":"Gill","year":"2004","journal-title":"JAMA"},{"key":"2020021316130956600_B31","doi-asserted-by":"crossref","first-page":"h2361","DOI":"10.1136\/bmj.h2361","article-title":"The role of intervening hospital admissions on trajectories of disability in the last year of life: prospective cohort study of older people","volume":"350","author":"Gill","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"2020021316130956600_B32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/107327481402100305","article-title":"Participation of the elderly population in clinical trials: barriers and solutions","volume":"21","author":"Denson","year":"2014","journal-title":"Cancer Contr"},{"key":"2020021316130956600_B33","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2003.09.124","article-title":"Barriers to clinical trial participation by older women with breast cancer","volume":"21","author":"Kemeny","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020021316130956600_B34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/leu.2015.230","article-title":"Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival","volume":"30","author":"Dinmohamed","year":"2016","journal-title":"Leukemia"},{"issue":"19","key":"2020021316130956600_B35","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020021316130956600_B36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"key":"2020021316130956600_B37","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation [published online ahead of print 4 March 2019]","author":"Ciurea","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2020021316130956600_B38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ajh.24963","article-title":"Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation","volume":"93","author":"Canaani","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2020021316130956600_B39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2217\/ahe.11.56","article-title":"The aging immune system and its relationship with cancer","volume":"7","author":"Foster","year":"2011","journal-title":"Aging Health"},{"issue":"4","key":"2020021316130956600_B40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1172\/JCI200522492","article-title":"Age-dependent incidence, time course, and consequences of thymic renewal in adults","volume":"115","author":"Hakim","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"2020021316130956600_B41","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2017-01-762658","article-title":"Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease","volume":"130","author":"Dudakov","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2020021316130956600_B42","doi-asserted-by":"crossref","first-page":"E2598","DOI":"10.1073\/pnas.1617933114","article-title":"Morphological features of IFN-\u03b3-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity","volume":"114","author":"Klinker","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2020021316130956600_B43","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2020021316130956600_B44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbmt.2012.11.006","article-title":"Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients","volume":"19","author":"Muffly","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020021316130956600_B45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41409-017-0021-4","article-title":"Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis","volume":"53","author":"Deschler","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2020021316130956600_B46","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jgo.2014.04.004","article-title":"Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates","volume":"5","author":"Holmes","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"2020021316130956600_B47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbmt.2016.09.027","article-title":"Allogeneic Stem Cell Transplantation for Patients Age \u2265 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT","volume":"23","author":"Heidenreich","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2020021316130956600_B48","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021316130956600_B49","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021316130956600_B50","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021316130956600_B51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2017.74.2270","article-title":"Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study","volume":"36","author":"Sharafeldin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021316130956600_B52","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bbmt.2013.06.008","article-title":"Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"19","author":"Brunner","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020021316130956600_B53","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"7","key":"2020021316130956600_B54","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"30","key":"2020021316130956600_B55","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020021316130956600_B56","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/17\/2608\/1716261\/advancesadv2019000155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/17\/2608\/1716261\/advancesadv2019000155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T02:18:11Z","timestamp":1721701091000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/17\/2608\/261358\/Haploidentical-transplantation-using"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":56,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000155","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]}}}